secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-023441
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026
--------------------------------------------------------------------------------

- Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.
- Lead candidate EB-003: completed pre-IND dose range studies, positive PTSD data, FDA pre-IND response; IND planned 2026.
- Hired Fish & Richardson to defend U.S. Patent 12,138,276 against Gilgamesh PGR; patent covers Bretisilocin (AbbVie, $1.2B).
- Completed reverse stock split 1:12 on Oct 28, 2025 after Nasdaq bid price deficiency delisting determination.
- Gross proceeds of ~$2.2M from warrant exercise; $7.9M net raised in first nine months of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/0001493152-25-023441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer